Natixis Advisors LLC Buys 319 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Natixis Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% during the 3rd quarter, Holdings Channel reports. The firm owned 117,002 shares of the biopharmaceutical company’s stock after buying an additional 319 shares during the period. Natixis Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $122,997,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. SteelPeak Wealth LLC raised its stake in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 692 shares during the period. Atria Investments Inc raised its stake in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares during the period. Tri Locum Partners LP lifted its holdings in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the last quarter. Tidal Investments LLC lifted its holdings in Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after purchasing an additional 711 shares during the last quarter. Finally, Catalytic Wealth RIA LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth $1,334,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $756.81 on Friday. The firm’s 50 day simple moving average is $985.21 and its 200 day simple moving average is $1,032.97. The firm has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $753.69 and a 1 year high of $1,211.20.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.